

# ACCESS DMD™



**An open-label, expanded access protocol intended to provide treatment with MP-104 (deflazacort)\* to U.S. children, adolescents, and/or adults with Duchenne muscular dystrophy is now available**

- ◆ The intent of an expanded access program is to provide patients with access to investigational medication for serious diseases or conditions where there is no comparable or satisfactory therapy available.
- ◆ The Food and Drug Administration (FDA) has authorized the use of deflazacort\*, an investigational medication for eligible patients with DMD, under the **ACCESS DMD™** expanded access program.
- ◆ As with any investigational medication that has not been approved by the FDA, deflazacort\* may or may not be effective in treating your DMD and there may be risks associated with its use.
- ◆ **ACCESS DMD™** participants will be provided deflazacort\* at no cost while participating in the program.
- ◆ Once ordered by an **ACCESS DMD™** participating physician, deflazacort\* will be sent directly to enrolled patients or their caregivers. Talk to your physician who treats your DMD about the possibility and risks of taking part in **ACCESS DMD™**.

\*Deflazacort is an investigational medication that has not been approved by the Food and Drug Administration (FDA) and is therefore not proven to be safe and effective.

To learn more about **ACCESS DMD™**, please visit [www.accessdmd.com](http://www.accessdmd.com)

The **ACCESS DMD™** team can be reached at: **1-844-800-4DMD**  
**(1-844-800-4363)**

